Gynecologic Cancers

Future research assessing cryocompression for those with gynecologic cancers will make use of different products to make the intervention easier and more accessible for patients.

Cryocompression demonstrates potential for preventing chemotherapy-induced neuropathy for those with gynecologic cancers, according to an expert from Duke University Medical Center.

Investigators report that most patients with gynecologic cancers were able to tolerate cryocompression to help manage chemotherapy-induced neuropathy, according to an expert from Duke University Medical Center.

Durvalumab plus tremelimumab and hypofractionated radiotherapy yields observable clinical benefits in patients with gynecologic cancers, according to an expert from The University of Texas MD Anderson Cancer Center.

Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.

Results from the ongoing phase 2 IMMUNOCERV trial showed that treatment with the investigational drug PDS0101 — a vaccine — combined with chemotherapy and radiation induced a 100% clinical response in a small group of patients with stage IB3 to IVA cervical cancer.

The FDA has granted mirvetuximab soravtansine-gynx an accelerated approval for the treatment of patients with folate receptor-α-positive platinum-resistant ovarian cancer based on results from the phase 3 SORAYA study.

Data from the phase 3 CALLA trial indicated that multidisciplinary collaboration and a good quality control strategy are key to providing optimal chemoradiotherapy delivery in locally advanced cervical cancer.

Results from the UK phase 2 PEACOCC trial found improved outcomes with pembrolizumab monotherapy in patients with previously-treated advanced clear cell gynecological cancers.

Ritu Salani, MD, highlights key data from the 2022 ESMO Congress, including those surrounding PARP inhibitor maintenance in advanced ovarian cancer and the latest developments in immunotherapeutics for endometrial and cervical cancer.

A recent study presented at IGCS 2022 looking at clinical trial enrollment found that Black patients experienced the biggest increase in accrual following an NCI call-to-action for more diversity in clinical trials.

At 2022 IGCS, Tiffany Sia, MD, spoke about using procedural interventions to treat patients with gynecologic malignancies who have oligoprogression on treatment with immune checkpoint inhibitors.

The 24-month follow-up of the phase 1/2 CheckMate 358 trial found nivolumab with or without ipilimumab yielded clinically meaningful, long-lasting responses in patients with recurrent or metastatic cervical cancer.

In a population of patients with cervical intraepithelial neoplasia and stage IA1 cervical cancer, certain local treatments, such as radical excision and ablation, were associated with treatment outcomes and risk of preterm birth.

Investigators reported that vaccinated patients had a higher rate of grade 2/3 cervical neoplasia due to non–vaccine preventable human papillomavirus compared with unvaccinated patients, an event commonly termed clinical unmasking.

Results from the phase 2 APPROVE trial showed apatinib plus pegylated liposomal doxorubicin improved efficacy and safety compared with pegylated liposomal doxorubicin alone for patients with platinum-resistant recurrent ovarian cancer.

Patients with advanced newly diagnosed ovarian, tubal, or peritoneal cancer did not derive further survival benefit from maintenance chemotherapy, although a modest improvement in progression-free survival was observed compared with surveillance.

Nutritional markers such as body mass index, weight loss, and albumin should be assessed to identify pre-operative malnutrition in patients with gynecologic cancers.

Patients with uterine carcinosarcoma who underwent sentinel lymph node biopsy or systemic lymph node dissection did not experience a difference in progression-free survival or overall survival.

Patients with advanced human papillomavirus 16–positive cervical cancer appear to benefit from treatment with VB10.16 and atezolizumab.

The phase 1/2 SPARTACUS trial assessed the use of stereotactic hypofractionated radiation therapy in patients with uterine cancer; the treatment appeared to be well tolerated.

Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

The safety and efficacy of NG-641 plus nivolumab will be assessed as part of the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumor.

Patients with advanced or recurrent uterine serous carcinoma derived promising benefit from treatment with ZN-c3.